Cellebrite (CLBT) CRO sells 411 shares to cover RSU tax obligations
Rhea-AI Filing Summary
Cellebrite DI Ltd. executive Jewell Marcus, Global Chief Revenue Officer, reported selling 411 ordinary shares of Cellebrite DI Ltd. on August 12, 2026 at a weighted average price of $16.0678 per share. A footnote explains the shares were originally granted as RSUs on February 11, 2025 and that the disposition is associated with tax obligations arising from the RSU vesting, effectively a sale to cover taxes. After this transaction, Marcus directly holds 439,690 ordinary shares. The transaction was not marked as conducted under a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 411 shares
Net Sell
1 txn
Insider
Jewell Marcus
Role
Global Chief Revenue Officer
Sold
411 shs ($7K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary shares, par value NIS 0.00001 F1, F2 | 411 | $16.0678 | $7K |
Holdings After Transaction:
Ordinary shares, par value NIS 0.00001 — 439,690 shares (Direct)
Footnotes (2)
- F1. The shares reported as disposed herein were granted on February 11, 2025, in the form of restricted stock units ("RSUs"). The disposition of shares is associated with tax obligations of the reporting person associated with the vesting of the RSUs.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.0086 to $16.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Key Figures
Shares sold: 411 shares
Weighted average sale price: $16.0678 per share
Post-transaction holdings: 439,690 shares
+3 more
6 metrics
Shares sold
411 shares
Ordinary shares sold on August 12, 2026
Weighted average sale price
$16.0678 per share
Average price for the 411 shares sold
Post-transaction holdings
439,690 shares
Direct ownership after the reported sale
Sale price range
$16.0086–$16.08 per share
Range of prices for multiple sale transactions
RSU grant date
February 11, 2025
Date the disposed shares were granted as RSUs
Transaction date
August 12, 2026
Date of the reported share sale
Key Terms
restricted stock units ("RSUs"), weighted average price, tax obligations
3 terms
restricted stock units ("RSUs") financial
"The shares reported as disposed herein were granted ... in the form of restricted stock units ("RSUs")."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
tax obligations financial
"The disposition of shares is associated with tax obligations of the reporting person associated with the vesting of the RSUs."
FAQ
What did Cellebrite (CLBT) insider Jewell Marcus report in this Form 4?
Jewell Marcus reported a sale of 411 ordinary shares of Cellebrite on August 12, 2026 at a weighted average price of $16.0678 per share, with the transaction linked to tax obligations from RSU vesting.
Was the CLBT insider sale by Jewell Marcus part of a Rule 10b5-1 trading plan?
No. The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and the footnotes do not indicate a trading plan, so the sale is not reported as made under a Rule 10b5-1 plan.
What role does Jewell Marcus hold at Cellebrite (CLBT) in this Form 4?
Jewell Marcus is identified as the company’s Global Chief Revenue Officer. The reported transaction therefore reflects an equity-related tax sale by a senior executive officer of Cellebrite DI Ltd.
AI-generated analysis. How Rhea-AI works. Not financial advice.